Crinetics Pharmaceuticals
Yahoo Finance • 5 months ago
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Crinetics Pharmaceuticals, Inc. SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therap... Full story
Yahoo Finance • 9 months ago
Crinetics Pharmaceuticals Inc Insider Sells Shares
Chief Scientific Officer Stephen Betz of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 3,000 shares of the company on January 10, 2024, according to a recent SEC Filing. The transaction was executed at a stock price of $37.65, resulting... Full story
Yahoo Finance • 10 months ago
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ...
Chief Med and Dev Officer Dana Pizzuti of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) sold 14,375 shares of the company on January 3, 2024, according to a recent SEC filing. The transaction was executed at an average price of $35 per share... Full story
Yahoo Finance • 10 months ago
Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares
On December 26, 2023, Stephen Betz, Chief Scientific Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), sold 3,000 shares of the company's stock, according to a recent SEC Filing. This transaction is part of a series of insider trades... Full story
Yahoo Finance • 10 months ago
Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ...
On December 21, 2023, Chief Med and Dev Officer Dana Pizzuti sold 9,583 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), as indicated by an SEC Filing. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused... Full story
Yahoo Finance • 11 months ago
12 Stocks Billionaire Steve Cohen Just Bought and Sold
In this article, we're going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought a... Full story
Yahoo Finance • 11 months ago
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida... Full story
Yahoo Finance • 11 months ago
Steven Cohen's Point72 Asset Management Adjusts Portfolio, Notably Reduces Adobe Stake
Insights from the Latest 13F Filing Highlight Key Investment Changes Steven A. Cohen, the renowned investor at the helm of Point72 Asset Management, has made significant changes to his investment portfolio in the third quarter of 2023. Co... Full story
Yahoo Finance • 12 months ago
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine dis... Full story
Yahoo Finance • 12 months ago
Insider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)
On November 1, 2023, Marc Wilson, the Chief Financial Officer (CFO) of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), sold 10,000 shares of the company. This move is part of a series of insider transactions that have been taking place over t... Full story
Yahoo Finance • last year
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine dis... Full story
Yahoo Finance • last year
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference... Full story
Yahoo Finance • last year
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine disease... Full story
Yahoo Finance • last year
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an Increase on Placebo (p<0.0001) After Switching from Injected Depot Standard of Care Mean A... Full story
Yahoo Finance • last year
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics' Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from ENDO President SAN DIEGO, June 21, 2023 (GLO... Full story
Yahoo Finance • last year
Crinetics to Highlight Broad Pipeline at ENDO 2023
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is... Full story
Yahoo Finance • last year
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-1 study topline data expected in 3Q 2023 Phase 3 PATHFNDR-2 study topline data expected in 1Q 2024 and enrollment target increased to up to 98 per prespecified protocol criteriaPaltusotine’s Phase 2 study in carcinoid synd... Full story
Yahoo Finance • 2 years ago
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023 Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in 1Q 2024 Pending a successful outcome from the PATHF... Full story
Yahoo Finance • 2 years ago
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that company management will participate in a fireside chat at the annual SVB Securities Global Biopharma Conference, which is being he... Full story
Yahoo Finance • 2 years ago
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
SAN DIEGO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being deve... Full story
